Ceribell (CBLL) Preferred Stock Liabilities (2023 - 2024)
Ceribell (CBLL) posted Preferred Stock Liabilities of $988000.0 for Q3 2024, down 99.33% on a QoQ basis from $147.4 million in Q2 2024, and down 99.33% year-over-year from $147.4 million in Q4 2023.
Ceribell (CBLL) Preferred Stock Liabilities (2023 - 2024) Analysis & Trends
Ceribell's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $988000.0 for Q3 2024.
- Quarterly Preferred Stock Liabilities fell 99.33% year-over-year to $988000.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $988000.0 (down 99.33% YoY) and the FY2023 annual result came in at $35.4 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $988000.0 for Q3 2024 at Ceribell, down from $147.4 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $147.4 million in Q3 2023 and bottomed at $988000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | - |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | - |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | - |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | - |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | - |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Ceribell | 613.16 Mn | 471.97 Mn | 23.12 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 988,000.00 |
| Jun 30, 2024 | 147.41 Mn |
| Mar 31, 2024 | 147.41 Mn |
| Dec 31, 2023 | 35.40 Mn |
| Sep 30, 2023 | 147.41 Mn |